Obstetric Hypertension Overview

Principles

Definition

Obstetric hypertension is a specialized domain within medical research dedicated to the comprehensive study of hypertensive disorders arising during pregnancy, labor, and the puerperium. This field investigates the epidemiology, pathophysiology, clinical presentation, diagnostic methods, management strategies, and prognostic implications of conditions such as gestational hypertension, preeclampsia, and eclampsia, recognizing their critical impact on maternal and perinatal morbidity and mortality.

Ontological type

Management Strategies

Classification Subtypes

Maternal Fetal Outcomes

Key developments

Key Figures

Vascular Pathogenesis Era era

S. Ananth Karumanchi [1] emerged as a leading figure in obstetric hypertension during the Vascular Pathogenesis Era, with affiliations at Harvard University [3] and Yale University [4]. His key contribution is highlighted by the 2003 paper [7] Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia, which anchored the vascular pathogenesis framework by linking placental signals to endothelial injury. Robert N. Taylor [2] was a prominent figure in the era, with affiliations at University of California, San Francisco [5] and Stanford University [6]. His 1989 paper Preeclampsia: An endothelial cell disorder [8] argued that preeclampsia is an endothelial cell disorder, a foundational concept for the vascular pathogenesis era and its emphasis on endothelial dysfunction and risk stratification.

Placental Angiogenic Era era

S. Ananth Karumanchi [1] conducted pivotal work at Harvard University [3] and The University of Texas Southwestern Medical Center [4] during the Placental Angiogenic Era. His key contributions, including the First Trimester Placental Growth Factor and Soluble Fms-Like Tyrosine Kinase 1 and Risk for Preeclampsia [7], the Soluble Endoglin and Other Circulating Antiangiogenic Factors in Preeclampsia [8], and Hypertension in Pregnancy [6], established that placental angiogenic imbalance underlies endothelial injury in preeclampsia and underpinned biomarker-based risk assessment. James M. Roberts [2] conducted influential work at Harvard University [3] and the University of California, San Francisco [5] during this era. His contributions, including Hypertension in Pregnancy [6], Uric Acid Is as Important as Proteinuria in Identifying Fetal Risk in Women With Gestational Hypertension [9], and Impairment of endothelial function in women with a history of preeclampsia: an indicator of cardiovascular risk [10], helped connect biomarkers and endothelial dysfunction to fetal risk and longer-term cardiovascular outcomes.

Lifecourse Cardiovascular Risk Era era

Laura A. Magee [1], affiliated with the University of Washington [3] and the University of Pittsburgh [4] during this era, contributed to obstetric hypertension research. Her key contributions include leading the 2021 ISSHP classification, diagnosis & management recommendations [7], co-authoring Hypertension in Pregnancy: Diagnosis, Blood Pressure Goals, and Pharmacotherapy: A Scientific Statement From the American Heart Association [8], and contributing to Hypertension Canada’s 2018 Guidelines for the Management of Hypertension in Pregnancy [9], which advanced standardized classification, diagnosis, and management and anchored a lifecourse cardiovascular risk approach. S. Ananth Karumanchi [2], affiliated with Harvard University [5] and Johns Hopkins University [6] during this era, contributed to obstetric hypertension research. His work on the ISSHP classification [7] and the AHA guidelines [8] helped standardize diagnosis and risk stratification, underpinning lifecourse prevention of cardiovascular disease in women.